BioSpace News Archive

Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q), is pleased to announce its lead compound RECCE® 327 (R327) has been added to The Pew Charitable Trusts’ annual list of Non-traditional Products in Development to Combat Bacterial Infections identifying new antibiotic treatments in development worldwide.

Biotech Acquisition Company (NASDAQ: BIOTU) (the “Company”) announced that, commencing March 18, 2021 , holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares (“Class A Ordinary Shares”) and warrants included in the units. No fractional warrants will be issue

Leatt Corporation, a developer and marketer of protective equipment and ancillary products for many forms of sports, especially extreme high-velocity sports, announced that its X-Frame Hybrid Knee Brace has received a 2021 Powersports Business Nifty 50 Award from the editors of Powersports Business.

Sobi™, a North American affiliate of the international biopharmaceutical company Swedish Orphan Biovitrum AB (publ) (Sobi®), dedicated to rare diseases, in partnership with the Platelet Disorder Support Association (www.pdsa.org PDSA), a leading immune thrombocytopenia (ITP) advocacy organization in North America, today announced the launch of florio®ITP

Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) announced today that it has entered into a definitive agreement for a business combination with Decoy Biosystems, Inc., a privately-held, preclinical-stage biotechnology company developing novel, multi-targeted products that safely prime both innate and adaptive anti-tumor and anti-viral immune responses.

- Newest member of the ACUVUE® OASYS Brand Family designed to deliver crisp, clear reliable vision at all distances, regardless of age or refractive error¹. - The new lens is designed for superior visual performance and a more precise fit∞¹.

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that David Johnson, Chairman and Chief Executive Officer, will participate in two upcoming investor conferences in March:

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced results from a real-world study of patients with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) who switched from prednisone to EMFLAZA® (deflazacort) following the FDA approval.

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the appointment of Michael Cordera as Executive Vice President and General Counsel.

Leaders from Kaiser Permanente, Northwell Health, and Manatt Ventures are featured on “Reimagine, Reboot, Retool: Healthcare Post-COVID,” a video panel posted by SXSW® Online.